An investigation for investors in Regulus Therapeutics Inc (NASDAQ:RGLS) shares over potential securities laws violations by Regulus Therapeutics was announced and NASDAQ:RGLS stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 07/07/2016 -- An investigation on behalf of investors of Regulus Therapeutics Inc (NASDAQ:RGLS) shares was announced concerning possible securities laws violations by San Diego, CA based biopharmaceutical company Regulus Therapeutics in connection certain financial statements.
Investors who purchased shares of Regulus Therapeutics Inc (NASDAQ:RGLS), have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on whether certain statements by Regulus Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On June 27, 2016, Regulus Therapeutics Inc announced during aftermarket hours that it received verbal notice from the U.S. Food and Drug Administration ("FDA") that the FDA had placed the Regulus Therapeutics' investigational new drug for the treatment of chronic hepatitis C virus infection on clinical hold after a second serious adverse event of jaundice was reported. Shares of Regulus Therapeutics Inc declined on June 28, 2016 to as low as $2.44 per share.
On July 5, 2016, NASDAQ:RGLS shares closed at $3.23 per share.
Those who purchased shares of Regulus Therapeutics Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego